1858-LB: A Novel GLP-1 Analog, GZR18, Induced an 18.6% Weight Reduction in Subjects with Obesity in a Phase Ib/IIa Trial

减肥 肥胖 还原(数学) 医学 相(物质) 内科学 内分泌学 数学 化学 几何学 有机化学
作者
Linong Ji,Wei Chen,RUIHUA DONG,Mingxia Yuan,Dong Zhao,SHUGUANG PANG,Liunuobei Zhao,Jing Zhao,ZHONG-RU GAN
出处
期刊:Diabetes [American Diabetes Association]
卷期号:73 (Supplement_1)
标识
DOI:10.2337/db24-1858-lb
摘要

It remains unclear whether the superior efficacy of multi-target incretin analogs versus single-target incretins in obesity treatment. This randomized, double-blind, placebo-controlled, dose-escalation phase Ib/IIa study aimed to assess the efficacy and safety of a GLP-1 analog, GZR18, in Chinese adults with obesity. The study investigated the weight loss potential of GZR18 and evaluated the feasibility of administrating GZR18 at different frequencies. Thirty-six participants with obesity were randomized 3:1 to receive 30 mg of GZR18 or a placebo for 35 weeks, including a 31-week dose-escalation period. Upon dose escalation to 9 mg/week, subjects were divided into dosing sub-cohorts of QW or Q2W. Endpoints were body weight change and AEs incidence. The average weight loss of GZR18 adjusted by placebo was 18.6% in QW group and 13.5% in Q2W group, with no IP-related serious AEs. Gastrointestinal AEs were reported most frequently, mainly in early dose-escalation period. GZR18 reduced body weight robustly and improved metabolic profiles in study participants. Its weight-loss effects surpassed those of Semaglutide (2.4 mg) and Tirzepatide (15 mg) in recent phase 3 trials involving similar Chinese populations (-9.8% and -17.5%, respectively). These findings warrant further investigation into GZR18's potential to offer superior weight management efficacy over multi-target incretin analogs. Disclosure L. Ji: None. W. Chen: None. R. Dong: None. M. Yuan: None. D. Zhao: None. S. Pang: None. L. Zhao: None. J. Zhao: None. Z. Gan: None.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
细腻盼烟发布了新的文献求助10
1秒前
2秒前
Ryan发布了新的文献求助10
2秒前
2秒前
高宇航发布了新的文献求助20
3秒前
houkangyi完成签到,获得积分10
4秒前
鲍鲍完成签到,获得积分10
4秒前
小鸣发布了新的文献求助40
5秒前
猫又完成签到,获得积分10
5秒前
欢喜灵13发布了新的文献求助10
7秒前
7秒前
一颗大树完成签到,获得积分10
8秒前
8秒前
promise发布了新的文献求助10
9秒前
完美世界应助庾储采纳,获得10
9秒前
水瓶鱼完成签到,获得积分10
11秒前
丘比特应助傲娇的云朵采纳,获得10
11秒前
小马甲应助欢喜灵13采纳,获得10
11秒前
12秒前
lianliyou发布了新的文献求助30
13秒前
mm发布了新的文献求助10
13秒前
14秒前
Yi77发布了新的文献求助30
14秒前
肥肥完成签到,获得积分10
14秒前
李神奇应助林代峰采纳,获得40
15秒前
17秒前
科目三应助平常山河采纳,获得10
17秒前
崔尔蓉发布了新的文献求助10
19秒前
宋宋完成签到,获得积分10
20秒前
xx关闭了xx文献求助
20秒前
21秒前
隐形曼青应助十三采纳,获得10
21秒前
21秒前
qxxx完成签到,获得积分20
22秒前
悦耳从寒完成签到,获得积分10
22秒前
23秒前
火星上博涛完成签到,获得积分20
23秒前
Yi77完成签到,获得积分20
23秒前
24秒前
24秒前
高分求助中
Sustainability in ’Tides Chemistry 2000
Sustainability in ’Tides Chemistry 1500
The ACS Guide to Scholarly Communication 1000
TM 5-855-1(Fundamentals of protective design for conventional weapons) 1000
Ethnicities: Media, Health, and Coping 800
Historia de la ciencia jurídica europea 600
Treatise on Geomorphology(2nd Edition - March 1, 2022) 520
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3070024
求助须知:如何正确求助?哪些是违规求助? 2724039
关于积分的说明 7483616
捐赠科研通 2371113
什么是DOI,文献DOI怎么找? 1257302
科研通“疑难数据库(出版商)”最低求助积分说明 609889
版权声明 596879